Compare CPA & FOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CPA | FOLD |
|---|---|---|
| Founded | 1947 | 2002 |
| Country | Panama | United States |
| Employees | N/A | N/A |
| Industry | Air Freight/Delivery Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.5B | 4.5B |
| IPO Year | 2005 | 2006 |
| Metric | CPA | FOLD |
|---|---|---|
| Price | $123.95 | $14.49 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 10 | 9 |
| Target Price | ★ $159.40 | $27.25 |
| AVG Volume (30 Days) | 354.8K | ★ 2.5M |
| Earning Date | 05-13-2026 | 05-06-2026 |
| Dividend Yield | ★ 6.09% | N/A |
| EPS Growth | N/A | ★ 50.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $15.51 | $20.50 |
| Revenue Next Year | $7.25 | $18.59 |
| P/E Ratio | $9.05 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $98.37 | $5.66 |
| 52 Week High | $156.41 | $14.50 |
| Indicator | CPA | FOLD |
|---|---|---|
| Relative Strength Index (RSI) | 56.22 | 74.18 |
| Support Level | $122.10 | $14.21 |
| Resistance Level | $122.76 | N/A |
| Average True Range (ATR) | 4.08 | 0.02 |
| MACD | 0.84 | -0.00 |
| Stochastic Oscillator | 71.30 | 100.00 |
Copa Holdings SA is a provider of airline passenger and cargo services through its subsidiaries. The company operates through the air transportation segment. It offers international air transportation for passengers, cargo, and mail, operating from its Panama City hub in the Republic of Panama, and domestic and international air transportation for passengers, cargo, and mail with a point-to-point route network through Copa Colombia, a Colombian air carrier. The company's geographical segments are North America, South America, Central America, and the Caribbean. It derives the maximum revenue from North America.
Amicus Therapeutics Inc is a biotechnology company focused to develop and deliver transformative medicines for people living with rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.